1-8 of 8
Sue Erickson-Viitanen
Close
Sort by
Journal Articles

Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

Abdulraheem Yacoub, Uma Borate, Raajit K Rampal, Haris Ali, Eunice Wang, Aaron T. Gerds, Gabriela S. Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, Stephen T Oh, Gary J. Schiller, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Naval Daver
Journal: Blood
Blood (2022) 140 (Supplement 1): 579–582.
https://doi.org/10.1182/blood-2022-160384
Published: 2022
Journal Articles

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

Abdulraheem Yacoub, Uma Borate, Raajit Rampal, Haris Ali, Eunice S. Wang, Aaron T. Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, Stephen Oh, Gary J. Schiller, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Naval Daver
Journal: Blood
Blood (2021) 138 (Supplement 1): 3647.
https://doi.org/10.1182/blood-2021-148668
Published: 2021
Journal Articles

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

Naval G. Daver, MD, Marina Kremyanskaya, MD PhD, Casey O'Connell, MD, Kim-Hien Dao, DO,PhD, Stephen T Oh, MD PhD, Aaron T. Gerds, MDMS, Srdan Verstovsek, MD PhD, Sue Erickson-Viitanen, PhD, Feng Zhou, Albert Assad, MD, Abdulraheem Yacoub, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 353.
https://doi.org/10.1182/blood-2018-99-111338
Published: 2018
Journal Articles

Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 × 10 9 /L): A Comparison to Patients with Normal or High Starting Platelet Counts

Moshe Talpaz, MD, Ronald Paquette, MD, PhD, Lawrence Afrin, MD, Solomon Hamburg, MD, PhD, Katarzyna Jamieson, MD, Howard Terebelo, DO, Gregory Ortega, MD, Roger M. Lyons, MD, Ramon V. Tiu, MD, BS, Elliott F. Winton, MD, Kavita Natrajan, MD, Olatoyosi Odenike, MD, Wei Peng, PhD, Victor A. Sandor, MD, CM, Peter O'Neill, MBA, CCRP, Sue Erickson-Viitanen, PhD, Lance Leopold, MD, Richard S Levy, MD, Hagop M Kantarjian, MD, Srdan Verstovsek, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 176.
https://doi.org/10.1182/blood.V120.21.176.176
Published: 2012
Journal Articles

Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-I)

Srdan Verstovsek, MD, PhD, Ruben A. Mesa, MD, Jason Gotlib, MD, MS, Richard S. Levy, MD, Vikas Gupta, MD, FRCP, FRCPath, John F. DiPersio, MD, PhD, John Catalano, MD, Michael W. Deininger, Carole B. Miller, MD, Richard T. Silver, MD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Murat O. Arcasoy, MD, Elizabeth Hexner, MD, Roger M. Lyons, MD, Ronald Paquette, MD, PhD, Azra Raza, MD, Kris Vaddi, PhD, Sue Erickson-Viitanen, PhD, William Sun, PhD, Victor A. Sandor, MD, CM, Hagop M. Kantarjian
Journal: Blood
Blood (2011) 118 (21): 5146.
https://doi.org/10.1182/blood.V118.21.5146.5146
Published: 2011
Journal Articles

Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I

Srdan Verstovsek, MD, PhD, Ruben A. Mesa, MD, Jason Gotlib, MD, MS, Richard S. Levy, MD, Vikas Gupta, MD, FRCP, FRCPath, John F. DiPersio, MD, PhD, John Catalano, MD, Michael W. Deininger, Carole B. Miller, MD, Richard T. Silver, MD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Murat O. Arcasoy, MD, Elizabeth Hexner, MD, Roger M. Lyons, MD, Ronald Paquette, MD, PhD, Azra Raza, MD, Kris Vaddi, PhD, Sue Erickson-Viitanen, PhD, William Sun, PhD, Victor A. Sandor, MD, CM, Hagop M. Kantarjian
Journal: Blood
Blood (2011) 118 (21): 278.
https://doi.org/10.1182/blood.V118.21.278.278
Published: 2011
Journal Articles

Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF,

Ruben A. Mesa, MD, Jason Gotlib, MD, MS, Vikas Gupta, MD, FRCP, FRCPath, John F. DiPersio, MD, PhD, John Catalano, MD, Michael W. Deininger, Alan Shields, PhD, Carole B. Miller, MD, Richard T. Silver, MD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Thomas Hare, PhD, Sue Erickson-Viitanen, PhD, William Sun, PhD, Victor A. Sandor, MD, CM, Richard S. Levy, MD, Hagop M. Kantarjian, Srdan Verstovsek, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 3842.
https://doi.org/10.1182/blood.V118.21.3842.3842
Published: 2011
Journal Articles

The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).

Srdan Verstovsek, Hagop M. Kantarjian, MD, Animesh D. Pardanani, MBBS, PhD, Deborah Thomas, MD, Jorge Cortes, MD, Ruben A. Mesa, MD, FACP, William J. Hogan, MBChB, John R. Redman, MD, Sue Erickson-Viitanen, Richard Levy, MD, Kris Vaddi, PhD, DVM, Edward Bradley, MD, Jordan Fridman, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2008) 112 (11): 1762.
https://doi.org/10.1182/blood.V112.11.1762.1762
Published: 2008